Zoetis (ZTS) Cost of Revenue (2012 - 2026)
Zoetis (ZTS) posted quarterly Cost of Revenue of $641.0 million for Q1 2026, up 3.72% year-over-year from $618.0 million in Q1 2025, and down 9.97% quarter-over-quarter from $712.0 million in Q4 2025.
Zoetis (ZTS) Cost of Revenue (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Cost of Revenue for 15 consecutive years, with $641.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue rose 3.72% year-over-year to $641.0 million; the TTM figure through Mar 2026 stood at $2.7 billion (changed 0.33% YoY), while the FY2025 annual figure was $2.7 billion, down 1.95% from the prior year.
- Cost of Revenue retreated to $641.0 million in Q1 2026 per ZTS's latest filing, from $712.0 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $728.0 million in Q4 2023 and bottomed at $569.0 million in Q1 2022.
- Historically, Cost of Revenue has averaged $649.2 million across 5 years, with a median of $643.0 million in 2024.
- Annual changes were most pronounced in 2023 — Cost of Revenue grew 11.49% — and 2025, when it declined 3.89%.
- Zoetis' Cost of Revenue stood at $653.0 million in 2022, then gained by 11.49% to $728.0 million in 2023, then retreated by 2.88% to $707.0 million in 2024, then increased by 0.71% to $712.0 million in 2025, then fell by 9.97% to $641.0 million in 2026.
- Business Quant data shows ZTS's Cost of Revenue at $641.0 million in Q1 2026, $712.0 million in Q4 2025, and $683.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn | 98.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 673.00 Mn |
| Jun 30, 2026 | 673.00 Mn |
| Mar 31, 2026 | 641.00 Mn |
| Mar 31, 2026 | 641.00 Mn |
| Dec 31, 2025 | 712.00 Mn |
| Dec 31, 2025 | 712.00 Mn |
| Sep 30, 2025 | 683.00 Mn |
| Sep 30, 2025 | 683.00 Mn |
| Jun 30, 2025 | 649.00 Mn |
| Jun 30, 2025 | 649.00 Mn |
| Mar 31, 2025 | 618.00 Mn |
| Mar 31, 2025 | 618.00 Mn |
| Dec 31, 2024 | 707.00 Mn |
| Dec 31, 2024 | 707.00 Mn |
| Sep 30, 2024 | 701.00 Mn |
| Sep 30, 2024 | 701.00 Mn |
| Jun 30, 2024 | 668.00 Mn |
| Jun 30, 2024 | 668.00 Mn |
| Mar 31, 2024 | 643.00 Mn |
| Mar 31, 2024 | 643.00 Mn |